LSV Healthcare Conferences is proud to present Europe Oncology Biomarkers and Clinical Development Congress to be held on the April 24-25, 2014 Germany. It is to be co-located with our Europe Outsourcing and Partnering in Clinical Trials Conference and Data Management in Clinical Trials Conference 2014.
Over the 2 days, the event will provide educational and networking opportunity for over 150 attendees to gain knowledge and insights into the Oncology biomarkers market.
Oncology biomarkers account for the lions share in the global biomarkers market and this market is forecast to grow at the highest growth rate in the next five years. The global oncology biomarkers market is expected to grow from $4.1 billion in 2009 to $9.5 billion in 2014 at a CAGR of 18.1% from 2009 to 2014. The key factors driving the growth of overall oncology biomarkers market sector include prevalence of cancer across the globe, the early diagnosis and enhanced testing capabilities biomarkers facilitate. LSV’s Inaugural Oncology Biomarkers and Clinical Development conference is designed to bring together leading industry, academic and government experts in oncology biomarkers market and molecular diagnostics together to will explore the progression of oncology biomarker research from initial discovery through to the development of fully validated companion diagnostics.
The event will bring together key scientists whose expertise is focused on biomarkers, companion diagnostics, personalized medicine, safety studies, translational medicine and decision making in the oncology therapeutic area from leading pharmaceutical, biotechnology, diagnostics, clinical research companies and academic institutions in the UK and Europe.
The global Oncology Biomarkers market is expected to grow from $4.1 billion in 2009 to $9.5 billion in 2014. The demand is increasing due to organizations trying to increase the success to failure rate of oncology drugs as well as the ability to trace the exact type of cancer and to be more specific with potential targets. Oncology biomarkers facilitate high-speed non-invasive cancer diagnosis and enhance screening and early cancer detection. The market offers high-growth opportunities with numerous initiatives to encourage biomarker-based cancer treatment.
This prestigious event provides a forum for practitioners and researchers to learn more about key solutions being provided to their industry, analysis of current technologies and their applications, network with their peers and address key industry concerns through a series of cutting edge conference presentations and interactive exhibition room in a professional yet relaxed environment.
Do not miss out on our co-located Europe Outsourcing and partnering in clinical trials conference and Data management in clinical trials conference which will bring together key scientists and investigators in oncology clinical trials, clinical R&D, adaptive trials, oncology diagnostics development, translational research and VPs, CEO,s Directors and Industry experts from leading pharmaceutical, biotechnology, diagnostics, clinical research companies and academic institutions in the UK and Europe.
Who will attend?
This is an exclusive event consisting of world-class keynote addresses and panel discussions designed specifically for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions.
Contacts:Mr. Shub Joshi Executive Director Conference business unit T: +91 (0) 8800 298 770 E: [email protected]